


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. Cancelled
2. (Currently Amended) The agent for renal failure according to claim 1, wherein the agent is a therapeutic or preventive agent for renal failure.
3. (Currently Amended) The agent for renal failure according to claim 2, wherein the agent is a therapeutic or preventive agent for acute renal failure.
4. (Currently Amended) The agent for renal failure according to claim 2, wherein the agent is a therapeutic or preventive agent for chronic renal failure.
5. (Currently Amended) An agent for renal failure according to claim 1, wherein the agent is a suppressive agent for the progression of renal failure.
6. (NEW) A method for suppressing the progression of renal failure comprising administering to a patient in need of such suppression a pharmaceutically effective amount of at least one oxaluric acid derivative represented by the following formula (I) or a pharmaceutically acceptable salt thereof as an effective ingredient:



wherein each of R_1 and R_2 , which may be the same or different, is hydrogen, an alkyl group or a cycloalkyl group, or R_1 and R_2 are joined to form a heterocyclic ring with the nitrogen atom to which they are both attached, and R_3 is hydrogen or an alkyl group.


7. (NEW) A method as claimed in claim 6 wherein R_3 is hydrogen.
8. (NEW) A method as claimed in claim 6 wherein R_2 is hydrogen.
9. (NEW) A method as claimed in claim 6 wherein R_1 is an alkyl group.
10. (NEW) A method as claimed in claim 9 wherein R_2 is hydrogen and R_3 is an alkyl group.
11. (NEW) A method as claimed in claim 6 wherein R_3 is an alkyl group.
12. (NEW) A method as claimed in claim 11 wherein R_1 is a cycloalkyl group.
13. (NEW) A method as claimed in claim 11 wherein R_1 and R_2 are joined to form a heterocyclic ring with the nitrogen atom to which they are both attached.
14. (NEW) A method as claimed in claim 6 wherein said at least one oxaluric

acid derivative comprises 5-methyloxaluric acid.

15. (NEW) A method as claimed in claim 6 wherein the renal failure is acute renal failure.

16. (NEW) A method as claimed in claim 6 wherein the renal failure is chronic renal failure.

17. (NEW) A method for suppressing the level of creatinine in blood comprising administering to a patient in need of such suppression a pharmaceutically effective amount of at least one oxaluric acid derivative represented by the following formula (I) or a pharmaceutically acceptable salt thereof as an effective ingredient:



wherein each of R₁ and R₂, which may be the same or different, is hydrogen, an alkyl group or a cycloalkyl group, or R₁ and R₂ are joined to form a heterocyclic ring with the nitrogen atom to which they are both attached, and R₃ is hydrogen or an alkyl group.


18. (NEW) A method as claimed in claim 17 wherein the increase of the

creatinine level in blood accompanied by the progression of renal failure is suppressed.

19. (NEW) A method as claimed in claim 17 wherein the renal failure is acute renal failure.

20. (NEW) A method as claimed in claim 17 wherein the renal failure is chronic renal failure.

21. (NEW) An agent for renal failure containing at least one oxaluric acid derivative represented by the following formula (I) or a pharmaceutically acceptable salt thereof as an effective ingredient:



wherein each of R_1 and R_2 , which may be the same or different, is hydrogen, an alkyl group or a cycloalkyl group, or R_1 and R_2 are joined to form a heterocyclic ring with the nitrogen atom to which they are both attached, and R_3 is hydrogen or an alkyl group.